Beta-catenin is elevated in human benign prostatic hyperplasia specimens compared to histologically normal prostate tissue

Tyler M Bauman; Chad M Vezina; Wei Huang; Paul C Marker; Richard E Peterson; William A Ricke

Beta-catenin is elevated in human benign prostatic hyperplasia specimens compared to histologically normal prostate tissue

Am J Clin Exp Urol. 2014 Dec 25;2(4):313-22. eCollection 2014.

Authors

Tyler M Bauman¹, Chad M Vezina², Wei Huang³, Paul C Marker⁴, Richard E Peterson⁵, William A Ricke⁶

Affiliations

¹ Department of Urology and Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health Madison, WI 53705, USA.
² Department of Comparative Biosciences, University of Wisconsin School of Veterinary Medicine Madison, WI 53706, USA ; University of Wisconsin O'Brien Urology Research Center Madison, WI, USA.
³ University of Wisconsin O'Brien Urology Research Center Madison, WI, USA ; Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health Madison, WI 53705, USA.
⁴ University of Wisconsin O'Brien Urology Research Center Madison, WI, USA ; Division of Pharmaceutical Sciences, University of Wisconsin School of Pharmacy Madison, WI 53705, USA.
⁵ Division of Pharmaceutical Sciences, University of Wisconsin School of Pharmacy Madison, WI 53705, USA.
⁶ Department of Urology and Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health Madison, WI 53705, USA ; University of Wisconsin O'Brien Urology Research Center Madison, WI, USA.

PMID: 25606577
PMCID: PMC4297327

Abstract

Benign prostatic hyperplasia (BPH) is linked to lower urinary tract symptoms (LUTS) such as incomplete bladder emptying, urinary frequency and urgency. Mechanisms responsible for BPH are not fully known. Here, we tested whether beta-catenin (CTNNB1) immunostaining intensity and distribution differ in human glandular BPH tissue specimens compared to normal prostate tissue. Multiplex immunostaining of CTNNB1, its putative transcriptional target gene lymphoid enhancer binding factor 1 (LEF1), and the epithelial marker E-cadherin were examined in clinical human prostate specimens with or without histological BPH (pure epithelial or mixed stromal-epithelial nodules). BPH specimens were obtained from 24 men who experienced LUTS and underwent transurethral resection of the prostate surgery. Control specimens were tumor-adjacent histologically normal prostate tissue from 48 patients who underwent radical prostatectomy. The resulting multispectral images were unmixed and optical densities recorded to quantify staining abundance, cellular (membranous, cytoplasmic, and nuclear) and tissue localization (stromal versus epithelial), and determination of percentage of CTNNB1-positive cells. The following CTNNB1 indices were significantly higher in BPH compared to normal prostate tissue: overall staining intensity, staining intensity in prostate stromal cell membranes, cytoplasm and nuclei, and prostate epithelial cell nuclei. The following LEF1 indices were significantly lower in BPH compared to tumor-adjacent normal prostate tissue: stromal LEF1 staining intensity, percentage of LEF1-positive stromal cells, and intensity of LEF1 staining in stromal cell membranes, cytoplasm, and nuclei. The percentage of stromal cells with CTNNB1(+)/LEF1(-) nuclei was higher and percentage of stromal cells with CTNNB1(-)/LEF1(+) nuclei was lower in BPH compared to tumor-adjacent normal prostate tissues. These results support the hypothesis that CTNNB1 expression increases in specific BPH tissue compartments. Further, since nuclear LEF1 staining does not coincide with cytoplasmic or nuclear CTNNB1 staining, it does not appear to be a reliable index of CTNNB1 activity in adult human prostate.

Keywords: LEF1; Prostate; beta-catenin; cellular localization; multispectral; stromal-epithelial; tissue microarray.

Abstract

Grants and funding